REPEAT - RavenQuest Secures Health Canada Cultivation License at Edmonton Facility
08 4월 2019 - 9:00PM
RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt:
1IT) (the “
Company” or
“
RavenQuest”) a federally-licensed producer of
cannabis, is pleased to announce it has secured a Health Canada
License to Cultivate at the Company’s flagship Edmonton
facility. The license allows RavenQuest to begin cannabis
production inside the revolutionary Orbital Garden 2.0 grow
technology at its ultra-modern Edmonton production facility.
The Edmonton facility increases RavenQuest’s production capacity by
275%, adding 7,000 kg of annual capacity and bringing the Company’s
total production capacity to approximately 11,000 kg per year.
George Robinson, CEO of RavenQuest, stated “this
is a very exciting time and inflection point for our
organization. This milestone catapults our company toward
dramatic cannabis production and revenue increases for 2019.
We have been busy preparing for this pivotal moment.
Our Edmonton team is ready and all equipment is in place, including
our Orbital Garden 2.0 technology. Starting material has been
carefully prepared and curated at our Markham facility and will be
moved to Edmonton to begin production immediately” Robinson
continued.
“Production will be ramped up rapidly and
efficiently in order to meet supply agreements with our provincial
partner, BCLDB, as well as major bulk buyer, Wayland Group” stated
Robinson. “We have already pre-sold all cannabis production
from our Markham and Edmonton facilities for the calendar year of
2019” he continued.
For more information, access RavenQuest’s
investor presentation, fact sheet and videos here.
About RavenQuest BioMed
Inc.
RavenQuest BioMed Inc. is a diversified publicly
traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized
research & development. RavenQuest is a licensed producer
with facilities located in Markham, Ontario and Edmonton,
Alberta.
RavenQuest maintains a research partnership with
McGill University focused upon cultivar (strain) recognition, plant
stabilization and yield maximization of the cannabis plant.
The Company focuses on partnerships with Indigenous
communities.
On Behalf of the Board of Directors
ofRAVENQUEST BIOMED INC.
"George Robinson"Chief Executive Officer
For further information, please contact: |
Mathieu McDonald, Corporate Communications |
|
1-877-282-1586 |
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding
Forward-Looking Statements
All statements in this press release, other than
statements of historical fact, are "forward-looking information"
with respect to the Company within the meaning of applicable
securities laws, including statements with respect to anticipated
production capacity. The Company provides forward-looking
statements for the purpose of conveying information about current
expectations and plans relating to the future and readers are
cautioned that such statements may not be appropriate for other
purposes. By its nature, this information is subject to
inherent risks and uncertainties that may be general or specific
and which give rise to the possibility that expectations,
forecasts, predictions, projections or conclusions will not prove
to be accurate, that assumptions may not be correct and that
objectives, strategic goals and priorities will not be
achieved. These risks and uncertainties include but are not
limited to those identified and reported in the Company’s public
filings under the Company’s SEDAR profile at www.sedar.com.
Although the Company has attempted to identify important factors
that could cause actual actions, events or results to differ
materially from those described in forward-looking information,
there may be other factors that cause actions, events or results
not to be as anticipated, estimated or intended. There can be no
assurance that such information will prove to be accurate as actual
results and future events could differ materially from those
anticipated in such statements. The Company disclaims any
intention or obligation to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise unless required by law.
Photos accompanying this announcement are available
at: http://www.globenewswire.com/NewsRoom/AttachmentNg/16c87072-cee6-4acf-8f37-0e0f24eca3b1
http://www.globenewswire.com/NewsRoom/AttachmentNg/329bea89-8d77-4849-8110-96089b4fb5f6
http://www.globenewswire.com/NewsRoom/AttachmentNg/72017ef7-339c-4987-ab1c-368973c972e9
http://www.globenewswire.com/NewsRoom/AttachmentNg/c2e8e11a-099f-41b1-8c0f-18dd591fb335
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024